Aurinia Pharmaceuticals Inc. (AUPH) Stock Forecast
AUPH analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.43 / 5 from 7 analysts
- Price target
- $17.86 average of analyst targets
- Upside to target
- +8.2% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.21
- 52-week range
- $11.58 – $18.62
AUPH analyst ratings
7 analystsNumber of analysts at each rating.
AUPH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AUPH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.22 | $0.21 | $0.25 | $0.23 | −4.3% | 5 |
| Current fiscal year (2026) | $0.94 | $0.90 | $1.01 | $2.07 | −54.4% | 5 |
| Next fiscal year (2027) | $1.07 | $0.51 | $1.64 | $0.94 | +13.0% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AUPH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $83.1M | $80.4M | $87.2M | +13.2% | 7 |
| Current fiscal year (2026) | $329.1M | $322.2M | $336.5M | +16.3% | 7 |
| Next fiscal year (2027) | $384.4M | $360.0M | $459.0M | +16.8% | 7 |
AUPH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AUPH revenue: reported and forecast
AUPH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.24 | $0.24 | $0.24 | $0.24 | $0.22 | −9.3% | 1 up · 2 down |
| Current fiscal year (2026) | $0.96 | $0.96 | $0.96 | $0.95 | $0.94 | −1.7% | 1 up · 2 down |
| Next fiscal year (2027) | $1.11 | $1.11 | $1.11 | $1.11 | $1.07 | −4.3% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AUPH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AUPH beat in 11 of 12.
What analysts expect from AUPH
7 analysts cover Aurinia Pharmaceuticals; their consensus rating is buy (4.43 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.86, 8.2% above the latest close of $16.51. Analysts expect earnings of $0.94 per share for 2026, −54.4% from a year earlier. For 2027 the average estimate is $1.07 per share on revenue of $384.4 million. Aurinia Pharmaceuticals beat the EPS estimate in 11 of the last 12 quarters.
Related: AUPH income statement, AUPH key metrics, AUPH chart. See the AUPH stock overview for the latest quote and news.
AUPH forecast FAQ
What is Aurinia Pharmaceuticals's price target?
The average analyst price target for Aurinia Pharmaceuticals is $17.86, 8.2% above the latest close of $16.51.
Is Aurinia Pharmaceuticals a buy, hold or sell?
Of 7 analysts covering Aurinia Pharmaceuticals, 5 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aurinia Pharmaceuticals's EPS forecast?
Analysts forecast $0.94 per share for 2026 (range $0.90 to $1.01); for 2027 the estimate is $1.07.
What is Aurinia Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $329.1 million, growth of 16.3%; for 2027 it is $384.4 million.
When does Aurinia Pharmaceuticals report earnings?
Aurinia Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $0.21.
Does Aurinia Pharmaceuticals usually beat earnings estimates?
Aurinia Pharmaceuticals reported EPS at or above the analyst estimate in 11 of the last 12 quarters.